Floatz logo

Ketoconazole

Astrocytic Tumor

Wake Forest University Health SciencesEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Astrocytic Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Oliver Jonas
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB

View all 40 →

Same molecule, other indications

Ketoconazole is also rated in:

breast cancerDormant
B
Indicative ·
57 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →
prostate adenocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →